Meeting Banner
Abstract #4104

Prostate Cancer localization with a Multiparametric MR Approach (PCaMAP): separating PCa from benign tissue in a multi-center study

Marnix C. Maas 1 , Alan J. Wright 1 , Kirsten M. Selns 2,3 , Masoom A. Haider 4 , Katarzyna J. Macura 5 , Daniel J.A. Margolis 6 , Berthold Kiefer 7 , Jurgen J. Ftterer 1 , and Tom W.J. Scheenen 1

1 Radiology, Radboud University Medical Center, Nijmegen, Netherlands, 2 Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 3 St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 4 Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, 5 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, United States, 6 UCLA David Geffen School of Medicine, Los Angeles, CA, United States, 7 Siemens AG Healthcare Sector, Erlangen, Germany

We present initial results of a multi-center trial aimed at assessing the diagnostic accuracy of 3T multi-parametric MR imaging and spectroscopy in distinguishing clinically significant prostate cancer (PCa) from other prostatic tissue, with whole-mount section histopathology as the gold standard. Good separation between PCa and benign tissues was found for multi-center ADC data; DCE and MRSI need further analysis before solid conclusions about these methods performance can be drawn. The validation part of this prospective trial will be used to determine the parameters contributing most to the detection and localization of clinically significant PCa as well as their optimal thresholds.

This abstract and the presentation materials are available to members only; a login is required.

Join Here